Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 58: | Line 58: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2014-06-08T20:58:08Z", | ||
"briefDesignDescription" : "Intensive glycemic therapy in T2DM", | "briefDesignDescription" : "Intensive glycemic therapy in T2DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0802743", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0802743", | ||
| Line 2,848: | Line 2,848: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2014-06- | "timestamp" : "2014-06-08T20:20:07Z", | ||
"briefDesignDescription" : "B-R vs. R-CHOP for indolent lymphomas", | "briefDesignDescription" : "B-R vs. R-CHOP for indolent lymphomas", | ||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2", | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2", | ||
"pageid" : 1664, | "pageid" : 1664, | ||
"pdfurl" : "http://bit.ly/1owpykX", | "pdfurl" : "http://bit.ly/1owpykX", | ||
"trainingLevel" : "fellow", | "trainingLevel" : "fellow\n}}", | ||
"citation" : "Rummel MJ, <i>et al</i>. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". <i>The Lancet</i>. 2013. 381(9873):1203-10.", | "citation" : "Rummel MJ, <i>et al</i>. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". <i>The Lancet</i>. 2013. 381(9873):1203-10.", | ||
"subspecialties" : "Oncology;Hematology", | "subspecialties" : "Oncology;Hematology", | ||